Australian Clinical Labs Ltd Financials

Market Capitalization A$514.7 Million as of July 1, 2024

Valuations Metrics as of May. 5, 2024

Trailing PE	30.50
Forward PE	12.84
Price to Sales TTM	A$0.73
Price to Book MRQ	A$2.97
Enterprise to Revenue	1.17
Enterprise to EBITDA	11.88

Financial Reports as of Jun. 30, 2023

Financials

Fiscal Year Ends	2023-06-30
Most Recent Quarter	2023-06-30
Profit Margin	2.29%
Operating Margin	6.95%
Return on Assets TTM	5.58%
Return on Equity TTM	9.19%

Income Statement

Revenue TTM	A$674,028,032
Revenue per Share TTM	A$3.36
Quarterly Revenue Growth	-6.40%
Gross Profit TTM	A$566,020,000
EBITDA	A$174,605,000
Net Income to Common TTM	A$15,432,000
Diluted EPS TTM	A$0.08
Quarterly Earnings Growth YoY	-80.50%

Balance Sheet

Total Cash MRQ	A$25,595,000
Total Cash per Share MRQ	A$0.13
Total Debt MRQ	A$
Total Debt to Equity MRQ	198.17
Current Ratio MRQ	0.66
Book Value per Share MRQ	A$0.82

Cash Flow

Operating Cash Flow TTM	A$153,943,008
Levered Free Cash Flow TTM	A$142,170,624

ACL Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	201,834,000
Float Shares	107,620,131
Avg 10 Volume	259,996
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	13.44%
% Held by Institutions	73.54%

Stock Price Summary

Beta	1.17
Fifty Two Week Low	A$2.26
Fifty Two Week High	A$3.67
Fifty Two Week Change	-46.72%
Day 50 MA	A$2.55
Day 200 MA	A$2.79

Dividends and Splits

Forward Annual Dividend Rate	A$0.12
Forward Annual Dividend Yield	4.92%
Trailing Annual Dividend Rate	A$0.10
Trailing Annual Dividend Yield	4.10%
Payout Ratio	182.77%
Dividend Date
Ex Dividend Date	2024-03-28
Last Split Factor
Last Split Date